ProShare Advisors
RVMD icon

ProShare Advisors’s Revolution Medicines RVMD Stock Holding History

ProShare Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
6,970
-1,895
-21% -$277K ﹤0.01% 739
2026
Q1 		$862K Buy
8,865
+326
+4% +$32.9K ﹤0.01% 830
2025
Q4 		$680K Buy
8,539
+1,878
+28% +$123K ﹤0.01% 973
2025
Q3 		$311K Sell
6,661
-294
-4% -$11.5K ﹤0.01% 1395
2025
Q2 		$256K Sell
6,955
-38,298
-85% -$1.47M ﹤0.01% 1560
2025
Q1 		$1.6M Sell
45,253
-9,849
-18% -$400K ﹤0.01% 703
2024
Q4 		$2.41M Buy
55,102
+16,438
+43% +$830K 0.01% 664
2024
Q3 		$1.75M Buy
38,664
+9,796
+34% +$427K ﹤0.01% 690
2024
Q2 		$1.12M Sell
28,868
-7,737
-21% -$289K ﹤0.01% 734
2024
Q1 		$1.18M Buy
36,605
+2,331
+7% +$69.1K ﹤0.01% 755
2023
Q4 		$983K Buy
34,274
+13,962
+69% +$335K ﹤0.01% 760
2023
Q3 		$562K Buy
20,312
+243
+1% +$7.21K ﹤0.01% 872
2023
Q2 		$537K Buy
20,069
+3,558
+22% +$87.3K ﹤0.01% 911
2023
Q1 		$358K Sell
16,511
-533
-3% -$13.1K ﹤0.01% 1095
2022
Q4 		$406K Buy
17,044
+1,458
+9% +$31K ﹤0.01% 1069
2022
Q3 		$307K Buy
15,586
+2,723
+21% +$59.8K ﹤0.01% 1139
2022
Q2 		$251K Sell
12,863
-5,954
-32% -$116K ﹤0.01% 1321
2022
Q1 		$480K Sell
18,817
-4,535
-19% -$98.7K ﹤0.01% 1301
2021
Q4 		$588K Buy
23,352
+23
+0.1% +$648 ﹤0.01% 1343
2021
Q3 		$642K Sell
23,329
-5,274
-18% -$154K ﹤0.01% 1067
2021
Q2 		$908K Buy
28,603
+7,224
+34% +$252K ﹤0.01% 1096
2021
Q1 		$981K Buy
21,379
+2,589
+14% +$116K ﹤0.01% 997
2020
Q4 		$744K Buy
+18,790
New +$743K ﹤0.01% 1019

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

ProShare Advisors's RVMD Position: Q2 2026 in Review

ProShare Advisors reduced its Revolution Medicines (RVMD) stake by 21% in Q2 2026, selling an estimated $277K and leaving 6,970 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #739.

ProShare Advisors first reported a position in RVMD in Q4 2020 and has held it in 23 quarters since. The position peaked at $2.41M in Q4 2024. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • ProShare Advisors held 6,970 shares of Revolution Medicines worth $1.31M as of Q2 2026.
  • ProShare Advisors sold 1,895 Revolution Medicines shares in Q2 2026, an estimated $277K.
  • Revolution Medicines made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #739 holding.
  • ProShare Advisors first reported a position in Revolution Medicines in Q4 2020 and has held it in 23 quarters since.
  • ProShare Advisors's Revolution Medicines position peaked at $2.41M in Q4 2024.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.